Various methods for determining the expression of the ␤-gene transfer. It could be demonstrated that GFP is genergalactosidase (␤-gal) gene after retroviral transduction ally superior to ␤-gal in terms of sensitivity, speed and nonwere compared as a means to assess retroviral titre. To invasiveness of assay, allowing easy direct FACS sorting allow better comparison, different retroviral vectors were of populations of transduced cells. This opens the possiconstructed carrying two mutants of the green fluorescent bility of enrichment by sorting of ex vivo transduced cells protein and assessed as sensitive markers of retroviral in gene therapy protocols.
Genes encoding easily assayable marker proteins are usedata presented indicate the feasibility of using the GFP gene as a marker gene for rapid FACS selection of vectorful for determining gene transfer efficiencies and promoter activities. The ␤-galactosidase (␤-gal) gene has transduced cells. Inclusion of GFP in retroviral vectors carrying therapeutic genes should facilitate ex vivo based been commonly used for this purpose and retroviral vectors carrying this gene have been constructed. 1 The gene therapies by allowing the facile enrichment of transduced cells. classic method for detecting ␤-gal activity involves fixation of cells or tissue sections followed by treatment Various rapid methods for assaying ␤-gal expression (X-gal staining, chemiluminescence and FACS analysis) with the colourless substrate X-gal, which is converted by ␤-gal to a blue compound. 2 More recently, methods were used to determine retrovirus-mediated gene transfer efficiencies and compared with the classical, but have been developed for the chemiluminescent detection of ␤-gal activity in cell extracts. 3 Unfortunately neither of slower, method of colony formation after growth in G418-containing medium. The pBAG vector was used for these methods allows live cells to be identified and cultured further. Fluorescence activated cell sorting (FACS) this comparison. 1 The estimated titre varies between has been used to overcome this problem, 4,5 but is hampered by significant cell death since the method involves a permeabilisation step to allow the chromogenic sub- experiments and depends on the method used. As an
The chemiluminescence assay is the least reliable of the three methods for determining ␤-gal expression, since it example, in one experiment chemiluminescence gave titres of around 0.25%, whereas X-gal staining gave titres is necessary to establish a calibration curve by mixing different ratios of ␤-gal expressing and nonexpressing cells. of 9.92% using the same cells. The commonly used method for estimating virus titre (G418 resistance) generIn order to extrapolate titre from chemiluminescence measurements, the distribution of ␤-gal expression levels ally gives lower titres, which may reflect the requirement for long-term expression (10 days) of the neomycin resistin the calibration curve must coincide with the distribution in the test population, necessitating a FACS analyance gene, compared to the relatively short-term expression (2-3 days) required for other methods. In the sis and comparison in every case. This is especially important in the light of the widespread use of biochemisame exemplary experiment, FACS analysis indicated that around 2.7% of the cells were infected. FACS analycal ␤-gal activity determination as a measure of transduction. A further disadvantage of this method is that it sis of infected cells also revealed a wide range of expression levels from 10 1 to 10 4 relative fluorescent light assays cell extracts and thus provides information about the average expression of ␤-gal in a population of cells units (not shown). This may account for variations in titre measured using methods of differing sensitivity.
rather than in the individual cell. bone. In six independent experiments the titres of both vectors were similarly low presumably due to the lack of an extended packaging signal in this vector (data not shown). In an effort to increase the titre, the EGFP gene was introduced into the LXSN-derived retroviral vector 9 under the transcriptional control of the MLV LTR, with or without a selectable neo/G418 marker gene (Figure 1 ). The hGFP gene under the control of the CMV promoter either in the sense or antisense orientation was also cloned into the pLXSN retroviral vector (Figure 1 ). All five of the EGFP-containing retroviral vectors gave similar transfection efficiencies (up to 59%) upon introduction into PA317 cells. 10 However, only three of the vectors (BAGEGFP, LXEGFP and LXSNEGFP) gave rise to infectious virus, as indicated by GFP expression in target NIH3T3 cells ( Figure 1) . As expected the transduction efficiency of the LXSN derived vectors 9 (LXEGFP and selected infected cells, such infected cells were tested at various times after infection in a FACS assay. The proportion of cells expressing EGFP remained constant over a period of 26 days after infection in three independent FACS allows the enrichment of a population of ␤-gal expressing cells.
4,5 However, permeabilisation of the cells experiments (Figure 2 ). The curves show that maximal expression levels were reached after 2 days and remain required to allow the non-fluorogenic ␤-gal substrate to enter causes considerable cell death as evidenced by the stable for more than 3 weeks. This demonstrates that the rapid GFP titre measurement on day 2 reflects the stable relatively high proportion of propidium iodide positive cells detectable. In contrast to the ␤-gal reporter gene, GFP titre measured on day 14. To investigate the potential application of this FACS GFP does not require an assay substrate. We thus sought to construct and compare analagous retroviral vectors technique for the rapid detection of successfully transduced cell types relevant for an ex vivo gene therapy carrying the GFP gene.
To determine which GFP gene would give the highest approach, the LXSNEGFP retroviral vector was used to infect lymphoid cells. In an initial experiment, the lymphlevels of expression in a number of commonly used cell lines, the wild-type GFP, a red-shifted excitation form oid cell lines J558 (murine B lymphocytes) and A301 (human T cell line) were transduced. After 10-14 days in (hGFP) in which the gene has been altered to codons that are preferentially used by mammalian cells and which G418 selection, a GFP-positive population was obtained from each cell population in which 72-76% expressed carries a point mutation in the chromophore (S65T), 7 as well as EGFP -a new form that carries an additional GFP at a high level (Figure 3 , lower panels). Even in the absence of G418 selection, which could not be applied in point mutation at amino acid 64 (F64L) and is reported to show enhanced expression, 8 were transfected into a a gene therapy protocol, 10% of J558 and 12.1% of the A301 cells could be shown to be infected. These infected variety of established cell lines and analysed for expression by FACS analysis. The wild-type GFP gave no cells again showed a wide range of expression levels ( Figure 3 , upper panels). detectable expression in all of the tested cell lines. EGFP consistently showed the highest level of expression in These data suggest that GFP may be an ideal marker system for the rapid selection of primary cells in ex vivo eight different cell lines of human (HT1080, 293, 293T, EJ), rodent (NIH3T3/PA317, Rat-2 and derived II,13) and retroviral transduction gene therapy protocols without cumbersome biochemical selection regimens. The feasifeline (CK) origin, up to 14.23-fold of that obtained after transfection of hGFP (Table 1) . In contrast hGFP gave bility of such an approach was further confirmed after transduction of human primary blood mononuclear cells slightly higher levels of expression than EGFP in COS-7 cells.
(PBMCs). The transduction efficiencies of PBMCs ranged from 1-4%, depending on the donor. To demonstrate that Based on these results, the more sensitive EGFP was chosen for insertion, in place of the ␤-gal gene, into the therapeutically relevant T lymphocytes were among the successfully transduced cells, FACS was performed after pBAG retroviral vector, allowing the comparison of the two marker genes in the context of the same vector backlabeling with phycoerythrin-labelled antiCD3 mono- 
